Correlations of CYP2C19 gene polymorphism with platelet inhibitionrate and clopidogrel low responsiveness
10.3969/j.issn.1006-5725.2018.01.032
- VernacularTitle:CYP2C19基因多态性与血小板抑制率及氯吡格雷低反应性的关系
- Author:
Hao WANG
1
;
Xiao ZHANG
;
Jifa ZHU
;
Junhui XING
Author Information
1. 郑州大学第一附属医院心血管内科
- Keywords:
CYP2C 19 genotype;
Thromboelastogram;
Platelet inhibition rate;
Clopidogrel low responsiveness
- From:
The Journal of Practical Medicine
2018;34(1):128-131
- CountryChina
- Language:Chinese
-
Abstract:
Objeetive To investigate the relationships of CYP2C19 genotype polymorphism with platelet inhibition rate and clopidogrel low responsiveness in patients taking percutaneous coronary intervention (PCI) during perioperative administration of clopidogrel.Methods 404 patients taking clopidogrel after PCI were included from February 2016 to February 2017.They were divided into three groups:fast metaboliszer,moderate metaboliszer and slow metabolizer,according to the CYP2C19 genotype.Platelet inhibition rate induced by adenosine diphosphate (ADP) was detected by thrombelastogram,platelet inhibition rate ＜ 30％ was defined as clopidogrel low responsiveness (CLR) group and the relationships between the three groups were analyzed in view of CYP2C19 genotype and the platelet inhibition rate and the clopidogrel low responsiveness.Results (1) The proportions of the three groups was 45.5％,45.3％ and 9.2％ in the 404 patients,no statistically significant difference among the three groups in general data (age,sex,platelet,hypertension,diabetes mellitus,hyperlipidemia) (P ＞ 0.05).(2) There was no statistically significant difference in the platelet inhibition rate between the three groups (P =0.312).(3) There was no significant difference in the clopidogrel low responsiveness between the three groups (P =0.295),with the fast metabolizer group vs.intermediate metabolizer (P =0.522),the fast metabolizer group vs.the slow metabolizer (P =0.117) and the intermediate metabolizer group vs.slow metabolizer (P =0.255).Conclusion There is no correlation of CYP2C19 genotype with platelet inhibition rate and clopidogrel low responsiveness in patients taking clopidogrel after PCI.Only the detection of CYP2C19 genotype may not accurately predict the antiplatelet aggregative activity of clopidogrel.
